ELTX$1.51-5.03%
Elicio Therapeutics, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$39.69M
Float & O/S:
Inst Own:
DilutionScan read 24 of Elicio Therapeutics, Inc.'s SEC filings and found 8 warrant series, 1 convertible, 3 ATM programs, 5 shelf registrations and 1 completed offering on file for ELTX. The latest dilution event on file is ATM sales on Jul 2, 2026. Analysis updated Oct 7, 2026.
Signal8 Summary
ELTX
Cash crisis with 2-month runway
Snapshot
Elicio Therapeutics is a clinical-stage biotech with no revenue, burning through cash to fund cancer vaccine trials. The company lost $39.6 million in FY 2025 and generated $37 million in negative free cash flow. It holds $18.6 million in cash against $14.5 million in debt.
What's Happening Right Now
- : The company published a peer-reviewed manuscript in Science Advances highlighting potent immune responses driven by its AMP-DNA adjuvant technology in preclinical models.
- : Elicio raised $13 million in net proceeds through its at-the-market program in Q1 and Q2 2026 to extend its cash runway past the mid-year trial readout.
- : Analysts highlight a looming cash crisis as Elicio approaches a pivotal Phase 2 trial readout for its KRAS vaccine, making 2026 a critical year for the company's survival.
